Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Generation and Assembly of Virus-Specific Nucleocapsids of the Respiratory Syncytial Virus09:08

Generation and Assembly of Virus-Specific Nucleocapsids of the Respiratory Syncytial Virus

4.1K
For in-depth mechanistic analysis of the respiratory syncytial virus (RSV) RNA synthesis, we report a protocol of utilizing the chaperone phosphoprotein (P) for coexpression of the RNA-free nucleoprotein (N0) for subsequent in vitro assembly of the virus-specific nucleocapsids...
4.1K
An Assay to Measure the Neutralizing Antibody Titer Specific for Respiratory Syncytial Virus05:01

An Assay to Measure the Neutralizing Antibody Titer Specific for Respiratory Syncytial Virus

713
This video demonstrates an assay for measuring neutralizing antibodies against respiratory syncytial virus (RSV). Pre-incubation with serum containing RSV-neutralizing antibodies neutralizes the virus particles, reducing cellular infection and plaque formation. Virus-infected cells are then subjected to fixation, blocking, and fluorophore-conjugated antibody labeling for plaque visualization. This process enables the identification of the highest serum dilution that neutralizes fifty percent of...
713
An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay09:14

An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay

11.5K
This study describes a high throughput, imaging-based micro-neutralization assay to determine the titer of neutralizing antibodies specific for respiratory syncytial virus (RSV). This assay format has been tested on different sample...
11.5K
Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses11:48

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

17.0K
We describe a method for generating and amplifying genetically modified respiratory syncytial viruses (RSVs) and an optimized plaque assay for RSVs. We illustrate this protocol by creating two recombinant viruses that respectively allow quantification of RSV replication and live analysis of RSV inclusion bodies and inclusion bodies-associated granules...
17.0K
An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection09:01

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

8.3K
Human respiratory syncytial virus (HRSV) can cause severe bronchiolitis in young infants. Part of the pathogenesis of severe HRSV disease is caused by the host immune response. Stimulation of primary human immune cells with HRSV provides a fast and reproducible model system to study activation of inflammatory pathways and...
8.3K
Remote Laboratory Management: Respiratory Virus Diagnostics14:56

Remote Laboratory Management: Respiratory Virus Diagnostics

33.6K
A rapidly-deployable, off-grid laboratory has been designed and built for remote, resource-constrained global settings. The features and critical aspects of the logistically-enhanced, expandable, multifunctional laboratory modules are explored. A checklist for a basic laboratory workflow and a protocol for a respiratory viral diagnostic test are developed and...
33.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pathogen spectra in hospitalised and nonhospitalised children with community-acquired pneumonia.

ERJ open research·2023
Same author

Filaggrin loss-of-function mutations are associated with persistence of egg and milk allergy.

The Journal of allergy and clinical immunology·2022
Same author

IRIS: Infection with RespIratory Syncytial Virus in infants-a prospective observational cohort study.

BMC pulmonary medicine·2022
Same author

Interobserver agreement in interpretation of chest radiographs for pediatric community acquired pneumonia: Findings of the pedCAPNETZ-cohort.

Pediatric pulmonology·2021
Same author

Persistent tachypnea of infancy: Follow up at school age.

Pediatric pulmonology·2020
Same author

PedCAPNETZ - prospective observational study on community acquired pneumonia in children and adolescents.

BMC pulmonary medicine·2019

Related Experiment Video

Updated: Jan 20, 2026

Generation and Assembly of Virus-Specific Nucleocapsids of the Respiratory Syncytial Virus
09:08

Generation and Assembly of Virus-Specific Nucleocapsids of the Respiratory Syncytial Virus

Published on: July 27, 2021

4.1K

[Respiratory syncytial virus].

Jürgen Seidenberg1

  • 1Universitätsklinik für Kinder- und Jugendmedizin, Klinik für Pädiatrische Pneumologie und Allergologie, Klinikum Oldenburg AöR, Rahel-Straus-Straße 10, 26133, Oldenburg, Deutschland. seidenberg.juergen@klinikum-oldenburg.de.

Der Internist
|September 6, 2019
PubMed
Summary

Respiratory syncytial virus (RSV) causes severe respiratory infections, especially in vulnerable populations like premature infants and the elderly. While detection is quick, effective treatments and prevention remain limited, though new antivirals are in development.

Keywords:
Antiviral agentsBronchiolitisPneumoniaRespiratory syncytial virus infectionsRisk factors

More Related Videos

An Assay to Measure the Neutralizing Antibody Titer Specific for Respiratory Syncytial Virus
05:01

An Assay to Measure the Neutralizing Antibody Titer Specific for Respiratory Syncytial Virus

713
An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
09:14

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay

Published on: January 26, 2019

11.5K

Related Experiment Videos

Last Updated: Jan 20, 2026

Generation and Assembly of Virus-Specific Nucleocapsids of the Respiratory Syncytial Virus
09:08

Generation and Assembly of Virus-Specific Nucleocapsids of the Respiratory Syncytial Virus

Published on: July 27, 2021

4.1K
An Assay to Measure the Neutralizing Antibody Titer Specific for Respiratory Syncytial Virus
05:01

An Assay to Measure the Neutralizing Antibody Titer Specific for Respiratory Syncytial Virus

713
An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
09:14

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay

Published on: January 26, 2019

11.5K

Area of Science:

  • Virology
  • Infectious Diseases
  • Public Health

Background:

  • Respiratory syncytial virus (RSV) is a major global cause of respiratory infections.
  • Severe illness, including bronchiolitis and pneumonia, affects preterm infants, infants, and the elderly, leading to high mortality rates.
  • Current preventive and therapeutic options for RSV are limited.

Purpose of the Study:

  • To highlight the significant global impact of RSV infections.
  • To underscore the vulnerability of specific populations to severe RSV disease.
  • To emphasize the unmet need for effective RSV interventions.

Main Methods:

  • Literature review on RSV epidemiology and clinical impact.
  • Analysis of current diagnostic capabilities for RSV.
  • Overview of existing and emerging therapeutic strategies.

Main Results:

  • RSV infection poses a substantial worldwide health burden.
  • High-risk groups experience severe outcomes, necessitating intensive care.
  • Rapid RSV detection contrasts with limited treatment and prevention.

Conclusions:

  • There is a critical need for enhanced preventive strategies and novel therapeutics for RSV.
  • Ongoing clinical trials for new antivirals offer potential future solutions.
  • Addressing the RSV burden requires continued research and development.